PDS Biotechnology (PDSB) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Pelthos Therapeutics (PTHS) over the past year, gaining 40.0% versus a loss of 24.5%. PDS Biotechnology is the larger company by market cap ($100.0 million vs $78.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | PTHS |
|---|---|---|
| Share price | $1.38 | $20.50 |
| Market cap | $100.01M | $78.48M |
| 1-day change | +35.29% | 0.00% |
| YTD return | +79.22% | -33.87% |
| 1-year return | +39.96% | -24.47% |
| 5-year return | -88.81% | — |
| EPS (TTM) | $-0.64 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $37.50 |
| 52-week low | $0.195 | $18.19 |
| Distance from 52-week high | -10.97% | -45.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +262.32% | +159.22% |
| Average volume | 23.24M | 60.07K |
| Shares outstanding | 72.47M | 3.83M |
| Employees | 21 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed PTHS by 64.4 percentage points over the past year.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
PDSB vs PTHS FAQ
Which is bigger, PDS Biotechnology or Pelthos Therapeutics?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $78.48M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, PDSB or PTHS?
PDSB returned +39.96% over the past 12 months, compared with -24.47% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Pelthos Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for PDS Biotechnology and Biotechnology: Biological Products (No Diagnostic Substances) for Pelthos Therapeutics.